Distribution of cytogenetic and mutation categories within ligand response groups
| Conventional prognostic factor . | Percent in entire cohort* (n) . | Percent in G-CSF sensitive* (n) . | Percent in G-CSF resistant* (n) . | P sensitive vs resistant . | Percent in response group SS* (n) . | Percent in response group RS* (n) . | Percent in response group SR* (n) . | Percent in response group RR* (n) . | P all groups . |
|---|---|---|---|---|---|---|---|---|---|
| Low-risk cytogenetics† | 32.6 (30) | 50 (11) | 26.6 (17) | .043 | 66.7 (4) | 42.9 (3) | 40 (6) | 24.6 (14) | .114 |
| Standard-risk cytogenetics‡ | 64.1 (59) | 50 (11) | 68.8 (44) | .114 | 33.3 (2) | 57.1 (4) | 60 (9) | 70.2 (40) | .300 |
| High-risk cytogenetics§ | 3.3 (3) | 0 | 4.7 (3) | .567 | 0 | 0 | 0 | 5.3 (3) | 1.000 |
| FLT3/ITD+ | 11.7 (15) | 5.1 (2) | 14.6 (12) | .222 | 0 | 14.3 (1) | 8.3 (2) | 14.7 (11) | .436 |
| FLT3/ITD− | 88.3 (113) | 94.9 (37) | 85.4 (70) | 100 (14) | 85.7 (6) | 91.7 (22) | 85.3 (64) | ||
| CEBPα mutated | 3.1 (4) | 7.7 (3) | 1.2 (1) | .098 | 0 | 0 | 12 (3) | 1.3 (1) | .119 |
| CEBPα WT | 96.9 (124) | 92.3 (36) | 98.8 (81) | 100 (13) | 100 (7) | 88 (22) | 98.7 (74) | ||
| NPM1 mutated | 8.8 (9) | 3.3 (1) | 12.1 (8) | .265 | 9.1 (1) | 0 | 0 | 13.1 (8) | .413 |
| NPM1 WT | 91.32 (93) | 96.7 (29) | 87.9 (58) | 90.9 (10) | 100 (5) | 100 (18) | 86.9 (53) |
| Conventional prognostic factor . | Percent in entire cohort* (n) . | Percent in G-CSF sensitive* (n) . | Percent in G-CSF resistant* (n) . | P sensitive vs resistant . | Percent in response group SS* (n) . | Percent in response group RS* (n) . | Percent in response group SR* (n) . | Percent in response group RR* (n) . | P all groups . |
|---|---|---|---|---|---|---|---|---|---|
| Low-risk cytogenetics† | 32.6 (30) | 50 (11) | 26.6 (17) | .043 | 66.7 (4) | 42.9 (3) | 40 (6) | 24.6 (14) | .114 |
| Standard-risk cytogenetics‡ | 64.1 (59) | 50 (11) | 68.8 (44) | .114 | 33.3 (2) | 57.1 (4) | 60 (9) | 70.2 (40) | .300 |
| High-risk cytogenetics§ | 3.3 (3) | 0 | 4.7 (3) | .567 | 0 | 0 | 0 | 5.3 (3) | 1.000 |
| FLT3/ITD+ | 11.7 (15) | 5.1 (2) | 14.6 (12) | .222 | 0 | 14.3 (1) | 8.3 (2) | 14.7 (11) | .436 |
| FLT3/ITD− | 88.3 (113) | 94.9 (37) | 85.4 (70) | 100 (14) | 85.7 (6) | 91.7 (22) | 85.3 (64) | ||
| CEBPα mutated | 3.1 (4) | 7.7 (3) | 1.2 (1) | .098 | 0 | 0 | 12 (3) | 1.3 (1) | .119 |
| CEBPα WT | 96.9 (124) | 92.3 (36) | 98.8 (81) | 100 (13) | 100 (7) | 88 (22) | 98.7 (74) | ||
| NPM1 mutated | 8.8 (9) | 3.3 (1) | 12.1 (8) | .265 | 9.1 (1) | 0 | 0 | 13.1 (8) | .413 |
| NPM1 WT | 91.32 (93) | 96.7 (29) | 87.9 (58) | 90.9 (10) | 100 (5) | 100 (18) | 86.9 (53) |
Percent of samples with specified cytogenetics within given category, among those samples with known cytogenetics. P values < .05 are shown in bold.
Low-risk cytogenetics: t(8;21) and inv(16).
Standard-risk cytogenetics: neither low nor high risk.
High-risk cytogenetics: monosomy 7, monosomy 5, del(5q).